Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3Observational 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3

Interventions

pembrolizumab 1258Specimen Handling 864Carboplatin 824Magnetic Resonance Spectroscopy 806Cyclophosphamide 798Cisplatin 719Nivolumab 660Paclitaxel 635Gemcitabine 570Radiotherapy 570Biopsy 526Bevacizumab 467Dexamethasone 441fludarabine 403Docetaxel 375venetoclax 369Oxaliplatin 363Capecitabine 355Fluorouracil 354atezolizumab 337Rituximab 333durvalumab 332Doxorubicin 316Pemetrexed 306Radiosurgery 304Drug Therapy 300Ipilimumab 296Standard of Care 288Etoposide 283Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × taletrectinib × 1 year × Clear all
NCT07154706 2026-05-19

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Nuvation Bio Inc.

Phase 3 Recruiting
180 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06564324 2026-04-13

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Nuvation Bio Inc.

Phase 3 Recruiting
194 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04919811 2026-01-07

TRUST-II

Nuvation Bio Inc.

Phase 2 Active not recruiting
217 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡